Prostate Cancer News and Research

Latest Prostate Cancer News and Research

ImaginAb and BZL Biologics conclude sublicense agreement for antibody technology

ImaginAb, Inc. and BZL Biologics, LLC have concluded a sublicense of BZL's PSMA/huJ591 antibody technology for the field of diagnostic imaging for PET and SPECT. "ImaginAb is pleased to have completed this [sub]licensing agreement with BZL as we believe that huJ591 will form the basis of an excellent clinical product for the diagnosis and management of prostate cancer.

12 Oct 2009

AACR to host its first Frontiers in Basic Cancer Research Meeting

The American Association for Cancer Research will host its first Frontiers in Basic Cancer Research Meeting in Boston from Oct. 8-11, 2009. The meeting is expected to draw nearly 500 leading scientists to present on high-profile topics like epigenetics, metastasis and systems biology, and create synergies among the many subfields of basic science.

12 Oct 2009

NIH awards Beth Israel Deaconess Medical Center $38.2M in grants

Beth Israel Deaconess Medical Center (BIDMC) has been awarded $38.2 million in funding from the National Institutes of Health (NIH) as part of the American Recovery and Reinvestment Act of 2009 (ARRA).

12 Oct 2009

Health Discovery retains Dilenschneider Group to manage its investor and media relations work

Health Discovery Corporation, is pleased to announce that it has retained The Dilenschneider Group, headquartered in New York City, to manage the Company’s investor and media relations work. With offices in New York, Washington, DC and Chicago, the Dilenschneider Group provides its clients with some of the finest and most seasoned communications professionals in the world.

9 Oct 2009

OncoGenex Pharmaceuticals president named Canada's Pacific Ernst & Young's Entrepreneur Of The Year

OncoGenex Pharmaceuticals, Inc., announced today that Scott Cormack, president and chief executive officer of OncoGenex, has been named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R). The Ernst & Young Entrepreneur Of The Year(R) Award is a high profile business award recognizing entrepreneurs that are building successful, dynamic businesses.

9 Oct 2009

Magnetic resonance imaging to help diagnose hidden prostate cancer

Clinical researchers at Princess Margaret Hospital (PMH) can now answer the question that baffles many clinicians - why do some men with elevated prostate specific antigen (PSA) levels who are carefully monitored and undergo repeated negative biopsies still develop aggressive prostate cancer?

9 Oct 2009

Urodynamix Technologies commences uroNIRS 2000 pilot program

Urodynamix Technologies Ltd. today announces that it has commenced a pilot sales and marketing program with Cardinal Health for its uroNIRS 2000, an innovative technology for the non-invasive diagnosis of bladder conditions. The 90-day pilot program will be used to by Urodynamix and Cardinal Health to evaluate the viability of adding the uroNIRS 2000 to Cardinal Health's catalogue of offerings to the urology market.

8 Oct 2009

New line of supplement products from Innovative Beverage Products

Amidst the cluttered counters within stores across the nation that contain countless copycat and unimaginative energy shots comes a new healthy twist and spark of vitality to the shot category. HealthShots(TM) - a new product line fortified with a host of healthy blends formulated specifically to taste great while also providing functional ingredients based on health and wellness concerns - has just launched in Long Island.

7 Oct 2009

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

OncoGenex Pharmaceuticals, Inc. announced today that OGX-011, also known as custirsen sodium, received an additional Fast Track Designation from the U.S. Food & Drug Administration (FDA) for progressive metastatic prostate cancer in combination with first-line docetaxel treatment.

6 Oct 2009

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

A new drug designed to "seek and destroy" common cancers such as breast, prostate, endometrial, pancreatic, ovarian, skin and testicular cancers is being tested at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare.

6 Oct 2009

BioImagene announces launch of the Virtuoso digital pathology solution

BioImagene, the leading provider of innovative digital pathology solutions, today announced the availability of the next generation of its digital pathology solution, VirtuosoTM. A highlight in this version is the ability to share cases in real time, allowing pathologists to collaborate with each other to sign out cases. Virtuoso users can participate in peer reviews, perform second-opinions for difficult cases, and guide residents in the review of cases for education.

6 Oct 2009

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

Las Vegas-based Endogenous Stem Cells Activators Inc. (ESAI) announced today that it will award a $1.3 million grant to Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LABioMed) for pre-clinical studies aimed at activating penile endogenous (adult) stem cells with the company's drug, KRONOS IV.

5 Oct 2009

Fifth SEEM anniversary meeting to be held in Belgrade

On 9 and 10 October the anniversary South Eastern European Meeting (SEEM) will be held in the Yugoslav Drama Theatre (Jugoslovensko Dramsko Pozoriste) in Belgrade (RS). Professor Michael Marberger (Vienna, AT), chairman of the Regional Office of the European Association of Urology: "For the 5th time the SEEM will provide a platform where new experimental and clinical work from the region is presented to an international audience".

5 Oct 2009

Prostate cancer and its influence on men's daily lives

Men who have prostate cancer often feel quite healthy, but the diagnosis still gives them a whole new outlook on life. Once they have learned to live with their cancer, they choose to focus on valuable relationships and appreciate the little things in life, shows a dissertation thesis from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

5 Oct 2009

Diagnocure signs agreement with Lab21 for marketing its Previstage test

DiagnoCure Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that it signed an exclusive agreement with a new partner, Lab21, a global provider of diagnostic products and services, for the promotion, marketing and selling of its Previstage(TM) GCC Colorectal Cancer Staging Test in the United Kingdom and Ireland.

5 Oct 2009

Seattle Cancer Care Alliance launches TheDayIFoundOut website for cancer patients

The day a person is diagnosed with cancer is one of the most difficult days of his or her life. While the Internet holds an endless supply of cancer related information, for an overwhelmed and frightened person, genuine emotional support is often hard to find. TheDayIFoundOut(TM) is an online community featuring the faces and voices of cancer survivors offering empathy, insight, advice and resources to help cancer patients take the first crucial steps toward beating their disease.

3 Oct 2009

CSPI sues Bayer for false claims on Men's One A Day multivitamins

The Center for Science in the Public Interest has sued the German drug company Bayer for falsely claiming that the selenium in Men's One A Day multivitamins might reduce the risk of prostate cancer. The lawsuit is filed in the Superior Court of California in San Francisco.

3 Oct 2009

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Quest PharmaTech Inc. ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. ("Paladin").

3 Oct 2009

New strategic research service for the oncology market launched by Health Strategies Group

Health Strategies Group, a leading provider of market intelligence to the pharmaceutical and biotechnology industries, has just launched Oncology Performance Edge, a new strategic research service that helps marketing and sales executives in the oncology field improve brand performance by understanding how best to invest their resources.

3 Oct 2009

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

Accuray Incorporated, a global leader in the field of radiosurgery, announced today publication of results from a study of early stage prostate cancer patients treated with CyberKnife Radiosurgery.

1 Oct 2009

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

ImaginAb and BZL Biologics conclude sublicense agreement for antibody technology

AACR to host its first Frontiers in Basic Cancer Research Meeting

NIH awards Beth Israel Deaconess Medical Center $38.2M in grants

Health Discovery retains Dilenschneider Group to manage its investor and media relations work

OncoGenex Pharmaceuticals president named Canada's Pacific Ernst & Young's Entrepreneur Of The Year

Magnetic resonance imaging to help diagnose hidden prostate cancer

Urodynamix Technologies commences uroNIRS 2000 pilot program

New line of supplement products from Innovative Beverage Products

OncoGenex' OGX-011 receives additional FDA Fast Track Designation for treating metastatic prostate cancer

EP-100 membrane-disrupting peptide drug for cancer being tested at TCRS

BioImagene announces launch of the Virtuoso digital pathology solution

LA BioMed granted $1.3M for investigating ESAI's KRONOS IV in correcting erectile dysfunction

Fifth SEEM anniversary meeting to be held in Belgrade

Prostate cancer and its influence on men's daily lives

Diagnocure signs agreement with Lab21 for marketing its Previstage test

Seattle Cancer Care Alliance launches TheDayIFoundOut website for cancer patients

CSPI sues Bayer for false claims on Men's One A Day multivitamins

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

New strategic research service for the oncology market launched by Health Strategies Group

Clinical study results of prostate cancer patients treated with CyberKnife Radiosurgery released

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in